Alpha-synuclein Aggregation Assay
With Human iPSC-Derived Neurons for Parkinson’s and dementia Research
Validate your drug candidate’s efficacy in our alpha-synuclein assay
Bioneer has over 100 publications in CNS research, including collaborations with Lundbeck and Johnson & Johnson.
With our human iPSC-derived neuronal model, using dopaminergic or cortical neurons, you can investigate disease mechanisms, evaluate potential therapeutics, or screen compounds that target disease pathways in Parkinson’s disease, dementia with Lewy bodies, and other alpha-synuclein–related neurodegenerative disorders.
The assay lets you induce alpha-synuclein aggregation in human neurons using fibril seeding and measure it with a sensitive FRET-based readout combined with phospho-specific α-synuclein antibodies.
This provides you with direct, quantitative insight into how your interventions influence alpha-synuclein accumulation in a biologically relevant, human-neuron context.
It is challenging to obtain commercially available preformed human alpha-synuclein fibrils of high potency and quality, optimized for human-relevant CNS models.
Our CDMO took up the challenge and is now manufacturing a recombinant Human Alpha-Syn Fibril product that provide us with the high quality, robust and reproducible aggregation results we have come to expect.
Click the button to submit your interest in the Evaluation Program and to be shortlisted for a free sample.
Applications
• Compound Screening
Screen and prioritize compounds that reduce α-synuclein aggregation
• Compound Evaluation
Evaluate effects of compounds on α-synuclein phosphorylation and accumulation
• Drug Discovery
Identify drug candidates with disease-modifying potential in a human neuronal context
• Preclinical Support
Support preclinical development with quantitative, human-relevant in vitro data
Gain Mechanistic Insight into Alpha-Synuclein Pathology
Key benefits of the Alpha-Synuclein Aggregation Assay
Disease-relevant neurons
We use human iPSC derived dopaminergic or cortical neurons, the main cell types affected in Parkinson’s disease, to ensure biological relevance.
Human iPSC-derived platform
We use scalable and reproducible human iPSC-derived neurons that closely reflect disease-relevant cell types and enable genetic engineering for translational research.
Translational model system
The assay incorporates inducible expression of the pathogenic A53T α-synuclein variant, reflecting known human disease genetics.
Quantitative measurement
FRET-based readout allows precise tracking of alpha-synuclein aggregation.
High specificity
Phospho-α-synuclein antibodies detect disease-relevant protein aggregates reliably.
Flexible study design
The assay can be adapted for screening, dose-response testing, or detailed mechanistic evaluations
Consistent and reproducible fibrils
We use our own recombinant human wildtype α-synuclein fibrils, produced and QCed in-house based on protocols developed by our experts, ensuring reproducible and well-characterized seeding activity.
Choosing us for your alpha-synuclein assay
Experts in neurodegenerative drug discovery
We are experts in neurodegenerative diseases and combine our specialized knowledge of the biological mechanisms driving neurodegeneration with advanced assay development.
Disease-specific assays
We cover the full spectrum, from cell engineering to assay development. This allows us to provide holistic guidance and support other aspects of your project or pipeline as needed. See our chain of CNS services here.
Established expertise
We´ve been serving the life science industry since 1982 with a strong foundation in science and technology.
Fast and creative initiators
Together, we co-create thoughtfully designed projects that bring efficiency and insights to your organization
Human-first approach
We believe in close collaboration, personal relationships, transparent and direct communication, and building trust that lasts
Related publications and posters
We have extensive experience in the CNS drug discovery space, with over 100 scientific publications that includes our collaborations with top pharma companies and leading research groups in the field. These publications reflect our expertise and key role in contributing to research and development across the field.
Our CNS leadership
Bjørn Holst,
Dept. Head of Cellular Engineering and Disease Models
Kenneth Thirstrup,
R&D Manager, CNS Assays
Example data of newly-developed alpha-synuclein seeding model
– Proprietary recombinant PFFs for improved drug screening & validation
Here you see: A robust co-culture seeding model enabling reproducible induction of α-synuclein aggregation using recombinant preformed fibrils (PFFs). Aggregation is quantified by high-content imaging of pS129 α-syn alongside neuronal markers, supporting reliable drug screening and validation.
-PFF
Hoechst, MAP2, pS129 α-syn
+PFF
Hoechst, MAP2, pS129 α-syn
FAQ: Alpha-synuclein aggregation assay
Practical Questions
Can I get a consultation to discuss my project?
Yes. By briefly filling out our contact form on this page, we’ll set up a no-obligation consultation to discuss your needs. We’re always happy to explore solutions and help you find the best path forward.
What information do you need from us to start an alpha-synuclein assay?
To initiate an alpha-synuclein assay, we would need a brief description of the number of compounds and concentrations to be tested, along with information on whether you wish to evaluate pre- and/or post-treatment effects.
What does the typical project process look like?
We usually start with an initial discussion to understand your objectives and define the scope of the project. Together, we then agree on a study design and timeline. During the project, we provide regular updates and remain very flexible, adapting our approach as needed to meet your goals.
At the end, you receive a comprehensive data package along with our scientific interpretation, and we remain available for follow-up questions or support.
What data outputs can I expect?
The assay provides quantitative readouts of intracellular α-synuclein aggregation levels, supported by antibody-based specificity. We deliver the results in a format that facilitates compound comparison, prioritization, and decision-making for drug development pipelines.
What is the typical timeframe for performing the alpha-synuclein assay?
The typical timeframe for performing the alpha-synuclein assay is approximately 8–10 weeks from project initiation to delivery of the final report.
Is the alpha-synuclein assay limited to a specific type of application?
No, the assay is versatile and can be applied across multiple stages of drug discovery and development.
It is well-suited for compound screening to identify agents that reduce α-synuclein aggregation, for evaluating therapeutic effects on phosphorylation and accumulation, and for supporting preclinical development with quantitative, human-relevant in vitro data. This makes it a valuable tool both for early discovery and later translational studies.
How is alpha-synuclein aggregation measured?
We use human iPSC-derived dopaminergic or cortical neurons engineered with a DOX-inducible copy of the α-synuclein gene carrying the pathogenic A53T mutation, linked to Parkinson’s disease. We initiate aggregation by adding α-synuclein fibrils and detect it using phosphorylation-specific antibodies in combination with fluorescence resonance energy transfer (FRET) technology.
This approach enables accurate quantification of intracellular α-synuclein aggregation and provides you with data to evaluate whether potential drug candidates can reduce or prevent this process.
Why does the α-synuclein aggregation assay use dopaminergic neurons or cortical neurons?
We use dopaminergic neurons to model early-stage Parkinson’s disease, as these neurons are particularly vulnerable to alpha-synuclein pathology. For later disease stages, or for dementia with Lewy bodies, we use cortical neurons, where alpha-synuclein–driven degeneration is closely linked to cognitive decline.
By selecting the neuron type that best matches your research question, the assay delivers data that more accurately reflects disease mechanisms and strengthens the translational relevance of your results.
Why are you using human iPSC-derived neurons?
Human iPSC-derived neurons provide a physiologically relevant model that closely mimics the cell types affected in human disease. They are scalable, reproducible, and can be genetically engineered to carry disease-relevant mutations or reporter constructs. Compared with primary human neurons, which are limited and variable, or rodent/immortalized cell lines, which may not fully reflect human biology, iPSC-derived neurons offer a reliable and ethically feasible platform for translational research
Can you measure both pre- and post-treatment effects of compound in relation to fibril treatment?
Yes. The assay is flexible, so it is possible to test the effect of compounds at different time-points.
What fibrils are you using to induce α-synuclein aggregation?
We are using fibrils generated from our own purified recombinant human wildtype α-synuclein monomer based on protocols developed in collaboration with experts within the field. The fibrils have been thoroughly QCed for α-synuclein purity and their ability to efficiently induce seeding in neurons.
Complementary capabilities
- Parkinsons Disease Models
- Seahorse assay
- Multielectrode array assay
- High content imaging
- Gene editing
- iPSC-derived astrocytes
- iPSC-derived neurons
Contact us for a free consultation
Interested in learning how we can support your project or pipeline?
We´re always happy to chat.
For further information please contact Business Development Manager Jacob Mathias Bech on jmb@bioneer.dk or +4523202576
For further information please contact Business Development Manager Jacob Mathias Bech on jmb@bioneer.dk or +4523202576
